Coronado Biosciences is focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. The company’s two principal pharmaceutical product candidates in clinical development include or CNDO-201 (TSO) for the treatment of autoimmune diseases, such as Crohn’s disease, ulcerative colitis (UC) and multiple sclerosis (MS); and CNDO-109, for the treatment of acute myeloid leukemia (AML).For more information, visit the company’s Web site at: www.coronadobiosciences.com

Noble Financial Capital Markets, an equity research driven, full-service, investment banking boutique, is hosting its ninth annual equity conference at The Hard Rock Hotel in Ft. Lauderdale, FL. Attended by institutional investors from across North America, the event features 135 public company executive teams with an emphasis on healthcare, technology, defense, and new-media / entertainment sectors.

Let us hear your thoughts below: